Activin receptor IIA ligand trap in chronic kidney disease: 1 drug to prevent 2 complications—or even more?

Kidney International

Volumn 89, Issue 6, 2016, Pages 1180-1182

  Massy, Ziad A ^a,b   Drueke, Tilman B ^b  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ACTIVIN A; ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR 2A; BONE MORPHOGENETIC PROTEIN; COLLAGEN TYPE 1; CYCLIC GMP; GROWTH DIFFERENTIATION FACTOR; MYELOPID; MYOSTATIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ACTIVIN RECEPTOR; LIGAND;

BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; ENDOCYTOSIS; HUMAN; KIDNEY FIBROSIS; LIGAND BINDING; LIGAND TRAP; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; CHRONIC KIDNEY FAILURE;

ACTIVIN RECEPTORS; ACTIVINS; HUMANS; LIGANDS; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION;

EID: 84978113435     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.02.006     Document Type: Note

References (9)

1. 1 Vervloet, M.G., Massy, Z.A., Brandenburg, V.M., CKD-MBD Working Group of ERA-EDTA. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes Endocrinol 2 (2014), 427–436.
2. 2 Cai, J., Pardali, E., Sánchez-Duffhues, G., ten Dijke, P., BMP signaling in vascular diseases. FEBS Lett 586 (2012), 1993–2002.
3. 3 Morrell, N.W., Bloch, D.B., Ten Dijke, P., et al. Targeting BMP signalling in cardiovascular disease and anaemia. [e-pub ahead of print]. Nat Rev Cardiol, 13 October 2015 http://dx.doi.org/10.1038/nrcardio.2015.156.
4. 4 Bagarova, J., Vonner, A.J., Armstrong, K.A., et al. Constitutively active ALK2 receptor mutants require type II receptor cooperation. Mol Cell Biol 33 (2013), 2413–2424.
5. 5 Muñoz-Félix, J.M., González-Núñez, M., Martínez-Salgado, C., López-Novoa, J.M., TGF-β/BMP proteins as therapeutic targets in renal fibrosis. Where have we arrived after 25 years of trials and tribulations?. Pharmacol Ther 156 (2015), 44–58.
6. 6 Lotinun, S., Pearsall, R.S., Davies, M.V., et al. A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys. Bone 46 (2010), 1082–1088.
7. 7 Dussiot, M., Maciel, T.T., Fricot, A., et al. An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. Nat Med 20 (2014), 398–407.
8. 8 Agapova, O.A., Fang, Y., Sugatani, T., et al. Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease. Kidney Int 89 (2016), 1231–1243.
9. 9 Sherman, M.L., Borgstein, N.G., Mook, L., et al. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women. J Clin Pharmacol 53 (2013), 1121–1130.